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Introduction


Biosimilars (aka follow-on biologics, subsequent-entry
biologics, biogenerics) very important for bending the cost
curve






high unit costs

more complex than chemically synthesized medicines

No biosimilar approval pathway prior to PPACA





fastest growing sector of the pharma market

FDA rulemaking still TBA

major challenges for the regulator (and the science)

Intellectual property (IP) issues



controversy over data vs market exclusivity
how long is enough / too long?
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From: Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the Nation’s
Biosimilars Program. N Engl J Med 2011; 365:385-388

Biologics


Therapeutics containing biotech-derived proteins as the
active substance(s)




Fastest growing sector of the pharma market





Costs high relative to small molecule drugs, so patent expiry
important

Most biologics are licensed under PHSA, but some are
approved under the FDCA.
Late 1970s and early 1980s, recombinant proteins &
monoclonal antibodies began to be developed





include vaccines, monoclonal antibodies, hormones

hormones (eg insulin and human growth hormone, heparins
drugs/CDER/FDCA

Antibodies, cytokines, immunomodulators, clotting factors
etc.


biologics/CBER/PHSA (though many transferred to CDER under
the PHSA in 2003)

Biologics vs small molecule meds

From: Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the Nation’s Biosimilars
Program. N Engl J Med 2011; 365:385-388

Licensing of generic medicines








Modern era of generics since Hatch-Waxman (Drug Price
Competition & Patent Term Restoration) Act of 1984.
Act established ANDA process – for products approved
under FDCA

allowing a generic to be licensed on the basis of bioequivalence
to a reference product

Bioequivalent = pharmaceutically equivalent and similar

bioavailability
 same amount of same active substance in the same dosage
form for the same route of administration and meeting the
same or comparable standards and with same bioavailability
 effect of drug on body the same and effect of body on drug the
same


If bioequivalent, generic may then “rely” on efficacy and
safety data submitted by the originator

avoids need to repeat costly (and arguably unethical) clinical
trials

Licensing of generic medicines











Pharmaceutical Equivalence (PE): same active
ingredients, dosage form, route, strength

Bioequivalence (BE): same rate & extent of absorption &
availability at site
Therapeutic Equivalence (TE) = PE + BE

Rule for 505(j) need PE + BE without need for clinical or
pre-clinical studies beyond BE
Substitutability needs Therapeutic Equivalence

505(b)(2)-full reports [some without right of ref]
Not limited to “sameness”; can be substitutable

Biologics vs follow-on biologics


Follow-on biologics are biological products that are able
to demonstrate a degree of similarity to an alreadyapproved product




Conceptually similar to generic small molecule medicines,
but can’t be approved on basis of bioequivalence

Biologics are more complex than chemically synthesised
meds




Follow on product may have the same DNA encoding
sequence but may differ in other key attributes

Unlikely any second manufacturer will be able to reproduce
precisely the process used by the originator

Protein Structures

Approval Pathway for Biosimilars



Hatch-Waxman provisions do not capture most biologics
Pathway set out in PPACA in Title VII (Biologic Price
Competition and Innovation Act 2010)





amends s351 of PHSA

pathway analogous to ANDA process - but with key
differences

BPCIA created serious scientific and policy challenges for
FDA








evidentiary requirements
how similar is similar?

is interchangeability possible? (biosimilar may be substituted
for the reference product without prescriber’s intervention)
nomenclature

pharmacovigilance

data/market exclusivity

Provisions of BPCIA
A follow-on biologic is required to demonstrate it is biosimilar
to a reference product based on data derived from

i) studies demonstrating that the biological product is highly similar
to the reference product (notwithstanding minor differences in
clinically inactive components);

ii) animal studies (including the assessment of toxicity); and

iii) clinical studies sufficient to demonstrate safety, purity, and
potency in one or more conditions for which reference product is
licensed.

The biosimilar and reference products must utilize the same






mechanism(s) of action (to the extent these are known);
route of administration,
dosage form,
strength and
proposed indication(s) and

the manufacturing facility must meet appropriate standards

Provisions of BPCIA - Interchangeability
“A (follow-on) biological product … may be deemed
interchangeable with the reference product… if it is





biosimilar to the reference product;

can be expected to produce the same clinical result in any given
patient; and
where administered more than once to a patient, the risks (in
terms of both efficacy and safety) of switching between the
follow-on biological product and the reference product are not
greater than the risks of using the reference product alone. “

and where ‘interchangeable’ is defined as


“… (able to) be substituted for the reference product without the
intervention of the health care provider who prescribed the
reference product.”

Scientific / Regulatory Challenges for FDA


FDA currently developing evaluation criteria to determine
how similar a biosimilar must be






Pharmacovigilance

even small changes in manufacturing process can affect S&E
 potential for immunogenicity a key issue
 critical to have identification of product for PV processes
For products claiming “interchangeability,” additional data
requirements.
 interchangeable products may be substituted for reference
product without reference to the prescriber
 standards to ensure biosimilar products that are not
interchangeable, are not substituted w/o prescriber’s consent.




these will likely vary according to product type
animal & clinical studies required “for the foreseeable future”
but scope and extent will vary
applicants will need to “carefully tailor” animal & human testing
to address any “residual uncertainty.

Safety / Immunogenicity


An immune response to a therapeutic protein can range
from clinically insignificant antibodies to a substantive
impact on safety and/or efficacy





Adverse immunogenic responses can include





immediate or delayed hypersensitivity reactions
cross-reaction with an endogenous protein

The ability to predict immunogenicity is very limited





neutralising antibody responses can reduce efficacy

some degree of clinical assessment of a new product's
immunogenic potential will ordinarily be needed.
epoetin alfa *

For a biosimilar to be interchangeable (substitutable)


repeated switching from the follow-on product to the reference
product (and vice versa) w/o adverse effects

* Macdougall IC. Pure red cell aplasia with anti-erythropoietin antibodies occurs more commonly with one
formulation of epoetin alfa than another. Current Medical Research and Opinion 2004 20;1:83-86.
Casadevall N, Nataf J, Viron B, et al. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated
with recombinant erythropoietin. N Engl J Med 2002;346:469-75

Hatch-Waxman and Data/Market
Exclusivity




Hatch-Waxman established minimum periods of
exclusivity for new chemical entities (NCEs).

Period commences on first day of registration of NCE






during which FDA may not accept an ANDA – or may not
approve it – irrespective of patent status of originator.

Confers monopoly protection via the regulatory process
in addition to that conferred by a patent
US has complex exclusivity schema

Data/Market Exclusivity






Market exclusivity for NCE – 5 years – with 4 years data
exclusivity
Plus 3 years for change in an approved drug product
 eg new indication, dosage strength, dosage form,
route of administration, patient population,
conditions of use
Orphan drug exclusivity – 7 years
Pediatric exclusivity – 6 months
 subject to FDA request for pediatric studies but trials
need not result in a labeling change
 extends Hatch-Waxman exclusivity by 6 months
 extends orphan drug exclusivity by 6 months
 also extends patent term by 6 months
 extends to all approved formulations, dosage forms
and indications
 more than one period of pediatric exclusivity possible

Exclusivity Schema before Biosimilars

And for biosimilars ...


Under BPCIA approval of a follow-on biologic application






Yet members of Congress say this “inconsistent with their
intentions”








“… may not be made effective … until 12 years after … the
reference product was first licensed”, and
“an application may not be submitted to the Secretary until 4
years” after that date”.
seems to be describing 4 years of DE and 12 years of ME

intended to provide 12 years of data exclusivity, not market
exclusivity.
to prevent the FDA from allowing another manufacturer to
rely on the data of an originator to support approval of
another product
but not to "… prevent another manufacturer from developing its
own data to justify FDA approval of a similar or competitive
product.”

President Obama’s 2012 budget proposal seeks to reduce
the 12 years of exclusivity to 7

Implications for the biosimilar market








Competition between originators and FOBs unlikely to model that
of generic and branded small molecules; originators likely to
maintain significant market share
BPCIA gives FDA substantial discretion but
 evidentiary requirements much greater than for small molecule
generics
 clinical trials to support claims of interchangeability and
exclude differences in immunogenicity much more expensive
and longer than the bioequivalence trials
Uncertainty and costs associated with biosimilars may limit the
number of players – enough to generate price competition?
Issue of acceptability of biosimilars to prescribers and patients.
FTC view that costs of FDA approval and developing manufacturing
capacity likely to limit the number of market entrants;
 lack of automatic substitution will limit rate and extent of
acquisition of market share;
 considers 12 years ME unnecessary to “protect innovation”
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